Noah Theiss

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer et al. · The Lancet Oncology · 2016 · 537 citations · Full text

Dll3-targeted Antibody-drug Conjugate, Medicine, Immunology +6

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)

Daruka Mahadevan, Noah Theiss, Carla Morales et al. · Oncotarget · 2014 · 31 citations · Full text

Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies

Sebastian Dziadek, Anton Kraxner, Wei‐Yi Cheng et al. · Frontiers in Immunology · 2024 · 27 citations · Full text

Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer

Marius Lund‐Iversen, Helge Scott, Erik H. Strøm et al. · Anticancer Research · 2018 · 11 citations · Full text

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Andreas Lundqvist, Vincent van Hoef, Xiaonan Zhang et al. · Journal for ImmunoTherapy of Cancer · 2016 · 11 citations · Full text